08:14 AM EDT, 05/12/2026 (MT Newswires) -- Collegium Pharmaceutical ( COLL ) said Tuesday that it has completed its acquisition of Azstarys from Corium Therapeutics.

Azstarys is intended to treat patients 6 years old and older with attention deficit hyperactivity disorder.

Collegium said it paid Corium Therapeutics approximately $650 million in cash, consisting of $350 million of cash on hand and $300 million from a delayed draw term loan, and may also pay another $135 million if Azstarys meets certain commercial and manufacturing milestones.

The company raised its net product revenue guidance for 2026 to a range of $865 million to $895 million, from $805 million to $825 million previously, to reflect the expected financial impact of the acquisition.